Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 701493, 16 pages
http://dx.doi.org/10.1155/2014/701493
Review Article

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

1Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
2Students Scientific Association at the Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland

Received 10 April 2014; Revised 22 September 2014; Accepted 23 September 2014; Published 30 October 2014

Academic Editor: Paola Perego

Copyright © 2014 Monika Podhorecka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Walawski, “Nowe leki i nowe podejście do leczenia a przeżycie chorych na nowotwory układu chłonnego,” Onkologia w Praktyce Klinicznej, vol. 4, no. 3, pp. 93–100, 2008. View at Google Scholar
  2. T. Wróbel, “Przeciwciała monoklonalne anty-CD20 w terapii chłoniaków agresywnych,” Hematologia, vol. 1, no. 4, pp. 342–351, 2010. View at Google Scholar
  3. J. Huszno, E. Nowara, and R. Suwiński, “Rola polimorfizmów genowych w terapii przeciwnowotworowej ukierunkowanej na cele molekularne—przeciwciała monoklonalne,” Onkologia Polska, vol. 14, no. 3, pp. 146–151, 2011. View at Google Scholar
  4. B. Powroźnik, P. Kubowicz, and E. Pękala, “Przeciwciała monoklonalne w terapii celowanej,” Postępy Higieny i Medycyny Doświadczalnej, vol. 66, pp. 663–673, 2012. View at Google Scholar
  5. Y. Kobayashi, “Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy,” Japanese Journal of Clinical Oncology, vol. 41, no. 2, pp. 157–164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Cang, N. Mukhi, K. Wang, and D. Liu, “Novel CD20 monoclonal antibodies for lymphoma therapy,” Journal of Hematology and Oncology, vol. 5, article 64, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Kirkwood, L. H. Butterfield, A. A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone, “Immunotherapy of cancer in 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 5, pp. 309–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Tomblyn, “Radioimmunotherapy for B-cell non-Hodgkin lymphomas,” Cancer Control, vol. 19, no. 3, pp. 196–203, 2012. View at Google Scholar · View at Scopus
  9. M. R. Chamarthy, S. C. Williams, and R. M. Moadel, “Radioimmunotherapy of non-Hodgkin's lymphoma: from the “magic bullets” to ‘radioactive magic bullets’,” Yale Journal of Biology and Medicine, vol. 84, no. 4, pp. 391–407, 2011. View at Google Scholar · View at Scopus
  10. B. Coiffier, S. Lepretre, L. M. Pedersen et al., “Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study,” Blood, vol. 111, no. 3, pp. 1094–1100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. W. G. Wierda, S. Padmanabhan, G. W. Chan, I. V. Gupta, S. Lisby, and A. Österborg, “Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study,” Blood, vol. 118, no. 19, pp. 5126–5129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. I. W. Flinn, W. N. Harwin, P. Ward et al., “Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated ChronicLymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL),” Blood, vol. 120, 2012, Abstract: No. 719. View at Google Scholar
  13. X. C. Badoux, M. J. Keating, S. Wen et al., “Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 31, no. 5, pp. 584–591, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-M. Wendtner, P. Hillmen, D. Mahadevan et al., “Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 53, no. 3, pp. 417–423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Czuczman, L. Fayad, V. Delwail et al., “Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study,” Blood, vol. 119, no. 16, pp. 3698–3704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Merli, A. Ferrario, C. Basilico et al., “Novel agents in indolent lymphomas,” Therapeutic Advances in Hematology, vol. 4, no. 2, pp. 133–148, 2013. View at Publisher · View at Google Scholar
  17. A. Srinivasan and S. K. Mukherji, “Tositumomab and iodine I 131 tositumomab (Bexaar),” American Journal of Neuroradiology, vol. 32, no. 4, pp. 637–638, 2011. View at Publisher · View at Google Scholar
  18. R. O. Dillman, “Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies,” Clinical and Experimental Medicine, vol. 6, no. 1, pp. 1–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. L. Wahl, “Tositumomab and 131I therapy in non-Hodgkin's lymphoma,” Journal of Nuclear Medicine, vol. 46, no. 1, pp. 128S–140S, 2005. View at Google Scholar · View at Scopus
  20. M. K. O'Reilly and J. C. Paulson, “Siglecs as targets for therapy in immune-cell-mediated disease,” Trends in Pharmacological Sciences, vol. 30, no. 5, pp. 240–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Hoelzer, “Novel antibody-based therapies for acute lymphoblastic leukemia,” Hematology, vol. 2011, pp. 243–249, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. D. Ricart, “Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin,” Clinical Cancer Research, vol. 17, no. 20, pp. 6417–6427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Zhu, Y. Ma, and D. Liu, “Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights,” Journal of Hematology and Oncology, vol. 3, article 17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. K. Duong and M. A. Sekeres, “Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin,” Clinical Interventions in Aging, vol. 4, pp. 197–205, 2009. View at Google Scholar · View at Scopus
  25. C. Nabhan, L. Rundhaugen, M. Jatoi et al., “Gemtuzumab ozogamicin (Mylotarg) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease,” Annals of Oncology, vol. 15, no. 8, pp. 1231–1236, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Katz, J. E. Janik, and A. Younes, “Brentuximab vedotin (SGN-35),” Clinical Cancer Research, vol. 17, no. 20, pp. 6428–6436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Reichert, “Antibody-based therapeutics to watch in 2011,” mAbs, vol. 3, no. 1, pp. 76–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Younes, N. L. Bartlett, J. P. Leonard et al., “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1812–1821, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. B. Skotnicki, W. S. Nowak, and M. Piotrowska, “Campath-1H (alemtuzumab)—nowy lek w terapii przewleklej bialaczki limfocytowej,” Acta Hematologica Polonica, vol. 34, no. 3, pp. 301–312, 2003. View at Google Scholar
  30. J. Lundin, E. Kimby, M. Björkholm et al., “Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL),” Blood, vol. 100, no. 3, pp. 768–773, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Hoelzer, “Novel antibody-based therapies for acute lymphoblastic leukemia,” Hematology/the Education Program of the American Society of Hematology. American Society of Hematology, vol. 2011, pp. 243–249, 2011. View at Publisher · View at Google Scholar
  32. J. M. Kirkwood, L. H. Butterfield, A. A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone, “Immunotherapy of cancer in 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 5, pp. 309–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Bello and E. M. Sotomayor, “Monoclonal antibodies for B-cell lymphomas: rituximab and beyond,” Hematology, pp. 233–242, 2007. View at Google Scholar · View at Scopus
  34. J. D. Shi, C. Bullock, W. C. Hall et al., “In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells,” Leukemia and Lymphoma, vol. 43, no. 6, pp. 1303–1312, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. A. P. Mone, P. Huang, H. Pelicano et al., “Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells,” Blood, vol. 103, no. 5, pp. 1846–1854, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Robak, “Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia,” Current Cancer Drug Targets, vol. 8, no. 2, pp. 156–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. P. Leonard and B. K. Link, “Immunotherapy of non-hodgkin's lymphoma with hll2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu I D 1 0 (apolizumab),” Seminars in Oncology, vol. 29, supplement 2, no. 1, pp. 81–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Rech, R. Repp, D. Rech et al., “A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study,” Leukemia and Lymphoma, vol. 47, no. 10, pp. 2147–2154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. K. J. Dunleavy, “Phase I study of combination of rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, p. 6607, 2005. View at Publisher · View at Google Scholar
  40. R. Stein, M. J. Mattes, T. M. Cardillo et al., “CD74: a new candidate target for the immunotherapy of B-cell neoplasms,” Clinical Cancer Research, vol. 13, no. 18, part 2, pp. 5556s–5563s, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Frölich, D. Blassfeld, K. Reiter et al., “The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression,” Arthritis Research &Therapy, vol. 14, no. 2, article R54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Starlets, Y. Gore, I. Binsky et al., “Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival,” Blood, vol. 107, no. 12, pp. 4807–4816, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. http://www.immunomedics.com/milatuzumab.shtml.
  44. J. D. Burton, S. Ely, P. K. Reddy et al., “CD74 is expressed by multiple myeloma and is a promising target for therapy,” Clinical Cancer Research, vol. 10, no. 19, pp. 6606–6611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Mark, P. Martin, J. P. Leonard, and R. Niesvizky, “Milatuzumab: a promising new agent for the treatment of lymphoid malignancies,” Expert Opinion on Investigational Drugs, vol. 18, no. 1, pp. 99–104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Binsky, M. Haran, D. Starlets et al., “IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 33, pp. 13408–13413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. G. L. Ong, D. M. Goldenberg, H. J. Hansen, and M. J. Mattes, “Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines,” Immunology, vol. 98, no. 2, pp. 296–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Sapra, R. Stein, J. Pickett et al., “Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys,” Clinical Cancer Research, vol. 11, no. 14, pp. 5257–5264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Alinari, B. Yu, B. A. Christian et al., “Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma,” Blood, vol. 117, no. 17, pp. 4530–4541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Stein, M. R. Smith, S. Chen, M. Zalath, and D. M. Goldenberg, “Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines,” Clinical Cancer Research, vol. 15, no. 8, pp. 2808–2817, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Christian, L. Alinari, C. Earl et al., “A phase I study of Milatuzumab a humanized anti-CD74 antibody and Veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-Cell Non-Hodgkin's Lymphoma,” [Abstract], 2010.
  52. Z. Berkova, R.-H. Tao, and F. Samaniego, “Milatuzumab-a promising new immunotherapeutic agent,” Expert Opinion on Investigational Drugs, vol. 19, no. 1, pp. 141–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Y. Wong and N. H. Dang, “Inotuzumab ozogamicin as novel therapy in lymphomas,” Expert Opinion on Biological Therapy, vol. 10, no. 8, pp. 1251–1258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Bello and E. M. Sotomayor, “Monoclonal antibodies for B-cell lymphomas: rituximab and beyond,” Hematology/the Education Program of the American Society of Hematology. American Society of Hematology, pp. 233–242, 2007. View at Google Scholar
  55. J. F. DiJoseph, D. C. Armellino, E. R. Boghaert et al., “Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies,” Blood, vol. 103, no. 5, pp. 1807–1814, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. D. A. Thomas, “Inotuzumab: the most active single agent in acute lymphoblastic leukemia?” Clinical Advances in Hematology and Oncology, vol. 10, no. 4, pp. 251–254, 2012. View at Google Scholar · View at Scopus
  57. A. Advani, E. G. Gisselbrecht, A. Rohatiner et al., “Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non Hodgkin’s lymphoma (NHL),” Blood, vol. 106, p. 230a, 2005. View at Google Scholar
  58. J. F. DiJoseph, M. M. Dougher, L. B. Kalyandrug et al., “Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma,” Clinical Cancer Research, vol. 12, no. 1, pp. 242–249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. J. F. de Vries, C. M. Zwaan, M. de Bie et al., “The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells,” Leukemia, vol. 26, no. 2, pp. 255–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Kebriaei, K. Wilhelm, F. Ravandi et al., “Feasibility of Allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin,” Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 3, pp. 296–301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Thomas, “Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia,” Expert Opinion on Investigational Drugs, vol. 21, no. 6, pp. 871–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Fayad, F. Offner, M. R. Smith et al., “Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab,” Journal of Clinical Oncology, vol. 31, no. 5, pp. 573–583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Ogura, K. Hatake, K. Ando et al., “Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma,” Cancer Science, vol. 103, no. 5, pp. 933–938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. R. R. Furman, M. Coleman, and J. P. Leonard, “Epratuzumab in non-Hodgkin's lymphomas,” Current Treatment Options in Oncology, vol. 5, no. 4, pp. 283–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. J. P. Leonard and D. M. Goldenberg, “Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies,” Oncogene, vol. 26, no. 25, pp. 3704–3713, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. S. J. Strauss, F. Morschhauser, J. Rech et al., “Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3880–3886, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. J. P. Leonard, S. J. Schuster, C. Emmanouilides et al., “Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma,” Cancer, vol. 113, no. 10, pp. 2714–2723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang, “Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma,” Blood, vol. 113, no. 24, pp. 6161–6171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. I. N. M. Micallef, M. J. Maurer, G. A. Wiseman et al., “Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma,” Blood, vol. 118, no. 15, pp. 4053–4061, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Morschhauser, F. Kraeber-Bodéré, W. A. Wegener et al., “High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 28, no. 23, pp. 3709–3716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. M. T. Kasner, “Novel targets for treatment of adult acute lymphocytic leukemia,” Current Hematologic Malignancy Reports, vol. 5, no. 4, pp. 207–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. E. A. Raetz, M. S. Cairo, M. J. Borowitz et al., “Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3756–3762, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Dörner, A. Shock, and K. G. C. Smith, “CD22 and autoimmune disease,” International Reviews of Immunology, vol. 31, no. 5, pp. 363–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Leonard, M. P. Coleman, J. Ketas et al., “Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results,” Clinical Cancer Research, vol. 10, no. 16, pp. 5327–5334, 2004. View at Google Scholar
  75. T. Dörner and D. M. Goldenberg, “Targeting CD22 as a strategy for treating systemic autoimmune diseases,” Therapeutics and Clinical Risk Management, vol. 3, no. 5, pp. 953–959, 2007. View at Google Scholar · View at Scopus
  76. J. P. Leonard, M. Coleman, J. Ketas et al., “Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5044–5051, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. J. M. Reichert, “Antibody-based therapeutics to watch in 2011,” MAbs, vol. 3, no. 1, pp. 76–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Niederfellner, A. Lammens, O. Mundigl et al., “Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies,” Blood, vol. 118, no. 2, pp. 358–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. P. J. Pauwels, C. Dumontet, J. M. Reichert et al., “7th cancer scientific forum of the Cancéropôle Lyon Auvergne Rhône-Alpes,” mAbs, vol. 4, no. 4, pp. 434–444, 2012. View at Publisher · View at Google Scholar
  80. V. Goede, K. Fischer, R. Busch et al., “Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions,” The New England Journal of Medicine, vol. 370, no. 12, pp. 1101–1110, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. D. M. Goldenberg, E. A. Rossi, R. Stein et al., “Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody,” Blood, vol. 113, no. 5, pp. 1062–1070, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. G. O. Negrea, R. Elstrom, S. L. Allen et al., “Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma,” Haematologica, vol. 96, no. 4, pp. 567–573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. A. R. Rezvani and D. G. Maloney, “Rituximab resistance,” Best Practice and Research: Clinical Haematology, vol. 24, no. 2, pp. 203–216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Morschhauser, P. Marlton, U. Vitolo et al., “Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma,” Annals of Oncology, vol. 21, no. 9, pp. 1870–1876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. G. L. Moore, H. Chen, S. Karki, and G. A. Lazar, “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions,” mAbs, vol. 2, no. 2, pp. 181–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Fournier, G. Delespesse, M. Rubio, G. Biron, and M. Sarfati, “CD23 antigen regulation and signaling in chronic lymphocytic leukemia,” Journal of Clinical Investigation, vol. 89, no. 4, pp. 1312–1321, 1992. View at Publisher · View at Google Scholar · View at Scopus
  87. N. I. Pathan, P. Chu, K. Hariharan, C. Cheney, A. Molina, and J. Byrd, “Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines,” Blood, vol. 111, no. 3, pp. 1594–1602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. J. C. Byrd, S. O'Brien, I. W. Flinn et al., “Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia,” Clinical Cancer Research, vol. 13, no. 15, part 1, pp. 4448–4455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. J. C. Byrd, T. J. Kipps, I. W. Flinn et al., “Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia,” Blood, vol. 115, no. 3, pp. 489–495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. L. M. Tourangeau, A. Kavanaugh, and S. I. Wasserman, “The role of monoclonal antibodies in the treatment of severe asthma,” Therapeutic Advances in Respiratory Disease, vol. 5, no. 3, pp. 183–194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. J. A. Poole, J. Meng, M. Reff, M. C. Spellman, and L. J. Rosenwasser, “Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects,” The Journal of Allergy and Clinical Immunology, vol. 116, no. 4, pp. 780–788, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Veliz and J. Pinilla-Ibarz, “Treatment of relapsed or refractory chronic lymphocytic leukemia,” Cancer Control, vol. 19, no. 1, pp. 37–53, 2012. View at Google Scholar · View at Scopus
  93. C. A. Chambers and J. P. Allison, “Costimulatory regulation of T cell function,” Current Opinion in Cell Biology, vol. 11, no. 2, pp. 203–210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. M. S. Czuczman, “Anti-CD80 monoclonal antibody: galiximab,” Haematologica Reports, vol. 1, no. 8, pp. 35–36, 2005. View at Google Scholar
  95. J. Plumas, L. Chaperot, M.-C. Jacob et al., “Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of costimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells,” European Journal of Immunology, vol. 25, no. 12, pp. 3332–3341, 1995. View at Publisher · View at Google Scholar · View at Scopus
  96. M. A. Martinez-Paniagua, M. I. Vega, S. Huerta-Yepez et al., “Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs,” Molecular Cancer Therapeutics, vol. 11, no. 3, pp. 572–581, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Bhat and M. S. Czuczman, “Galiximab: a review,” Expert Opinion on Biological Therapy, vol. 10, no. 3, pp. 451–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. S. M. Smith, H. Schöder, J. L. Johnson, S.-H. Jung, N. L. Bartlett, and B. D. Cheson, “The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: cancer and Leukemia Group B 50602 (Alliance),” Leukemia and Lymphoma, vol. 54, no. 7, pp. 1405–1410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. M. S. Czuczman, A. Thall, T. E. Witzig et al., “Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4390–4398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. M. S. Czuczman, J. P. Leonard, S. Jung et al., “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): follicular lymphoma international prognostic index (FLIPI) score is predictive of upfront immunotherapy responsiveness,” Annals of Oncology, vol. 23, no. 9, Article ID mdr620, pp. 2356–2362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. A. B. Gottlieb, S. Kang, K. G. Linden et al., “Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis,” Clinical Immunology, vol. 111, no. 1, pp. 28–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. E. J. Feldman, M. Kalaycio, G. Weiner et al., “Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195,” Leukemia, vol. 17, no. 2, pp. 314–318, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. E. J. Feldman, J. Brandwein, R. Stone et al., “Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4110–4116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. M. K. Sutherland, C. Yu, M. Anderson et al., “5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia,” mAbs, vol. 2, no. 4, pp. 440–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Miederer, M. R. McDevitt, G. Sgouros, K. Kramer, N.-K. V. Cheung, and D. A. Scheinberg, “Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates,” Journal of Nuclear Medicine, vol. 45, no. 1, pp. 129–137, 2004. View at Google Scholar · View at Scopus
  106. T. L. Rosenblat, M. R. McDevitt, D. A. Mulford et al., “Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia,” Clinical Cancer Research, vol. 16, no. 21, pp. 5303–5311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. M. A. Schwartz, D. R. Lovett, A. Redner et al., “Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias,” Journal of Clinical Oncology, vol. 11, no. 2, pp. 294–303, 1993. View at Google Scholar · View at Scopus
  108. G. Borthakur, M. G. Rosenblum, M. Talpaz et al., “Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies,” Haematologica, vol. 98, no. 2, pp. 217–221, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. G. Van Kooten and J. Banchereau, “CD40-CD40 ligand,” Journal of Leukocyte Biology, vol. 67, no. 1, pp. 2–17, 2000. View at Google Scholar · View at Scopus
  110. A. W. Tong and M. J. Stone, “Prospects for CD40-directed experimental therapy of human cancer,” Cancer Gene Therapy, vol. 10, no. 1, pp. 1–13, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Khubchandani, M. S. Czuczman, and F. J. Hernandez-Ilizaliturri, “Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies,” Current Opinion in Investigational Drugs, vol. 10, no. 6, pp. 579–587, 2009. View at Google Scholar · View at Scopus
  112. R. Advani, A. Forero-Torres, R. R. Furman et al., “Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4371–4377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Forero-Torres, N. Bartlett, A. Beaven et al., “Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma,” Leukemia and Lymphoma, vol. 54, no. 2, pp. 277–283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. Y.-T. Tai, X.-F. Li, L. Catley et al., “Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications,” Cancer Research, vol. 65, no. 24, pp. 11712–11720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. R. Lapalombella, A. Gowda, T. Joshi et al., “The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 144, no. 6, pp. 848–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. E. Agura, R. Niesvizky, J. Matous et al., “Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study,” Blood, vol. 114, no. 22, p. 2870, 2009, (ASH Annual Meeting Abstracts). View at Google Scholar
  117. http://clinicaltrials.gov/show/NCT00664898.
  118. M. Luqman, S. Klabunde, K. Lin et al., “The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells,” Blood, vol. 112, no. 3, pp. 711–720, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Freedman, S. Kuruvilla J, S. Assouline et al., “Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592),” in 53rs ASH Annual Meeting and Exposition, Session: Lymphoma—Therapy with Biologic Agents, Excluding Pre-Clinical Models: Immunotherapeutics and Small Molecule Inhibitors, December 2011.
  120. J. C. Byrd, T. J. Kipps, I. W. Flinn et al., “Phase i study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 53, no. 11, pp. 2136–2142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. W. Bensinger, R. T. Maziarz, S. Jagannath et al., “A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma,” British Journal of Haematology, vol. 159, no. 1, pp. 58–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. http://clinicaltrials.gov/ct2/show/NCT01275209.
  123. http://clinicaltrials.gov/show/NCT00670592.
  124. M. Fanale, S. Assouline, J. Kuruvilla et al., “Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma,” British Journal of Haematology, vol. 164, no. 2, pp. 258–265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. T. M. Seiler and W. Hiddemann, “Advances in the management of follicular lymphoma,” Current Opinion in Oncology, vol. 24, no. 6, pp. 742–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Nagorsen and P. A. Baeuerle, “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Experimental Cell Research, vol. 317, no. 9, pp. 1255–1260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Wang, G. Wei, and D. Liu, “CD19: a biomarker for B cell development, lymphoma diagnosis and therapy,” Experimental Hematology & Oncology, vol. 1, no. 1, article 36, 2012. View at Publisher · View at Google Scholar
  128. S. d'Argouges, S. Wissing, C. Brandl et al., “Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells,” Leukemia Research, vol. 33, no. 3, pp. 465–473, 2009. View at Publisher · View at Google Scholar
  129. “Background information for the pediatric subcommittee of the oncologic drugs advisory committee meeting,” Meeting Background Materials, December 2012.
  130. M. S. Topp, N. Goekbuget, G. Zugmaier et al., “Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed b-precursor all: updated results of an ongoing phase II trial,” ASH Annual Meeting Abstracts, vol. 118, no. 21, p. 252, 2011. View at Google Scholar
  131. M. S. Topp, P. Kufer, N. Gökbuget et al., “Targeted therapy with the T-cell—engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival,” Journal of Clinical Oncology, vol. 29, no. 18, pp. 2493–2498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. M. S. Topp, N. Gökbuget, G. Zugmaier et al., “Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL,” Blood, vol. 120, no. 26, pp. 5185–5187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Grothey and E. Galanis, “Targeting angiogenesis: progress with anti-VEGF treatment with large molecules,” Nature Reviews Clinical Oncology, vol. 6, no. 9, pp. 507–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab.
  135. Y. Odia, J. H. Shih, T. N. Kreisl, and H. A. Fine, “Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort,” Journal of Neuro-Oncology, 2014. View at Publisher · View at Google Scholar
  136. G. J. Ossenkoppele, G. Stussi, J. Maertens et al., “Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK),” Blood, vol. 120, no. 24, pp. 4706–4711, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. J. E. Karp, I. Gojo, R. Pili et al., “Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab,” Clinical Cancer Research, vol. 10, no. 11, pp. 3577–3585, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. K. S. Reiners, A. Gossmann, E. P. Von Strandmann, B. Böll, A. Engert, and P. Borchmann, “Effects of the anti-VEGF Monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed hodgkin lymphoma,” Journal of Immunotherapy, vol. 32, no. 5, pp. 508–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Foss, I. D. Araujo, G. Demel et al., “Expression of vascular endothelial growth factor in lymphomas and Castleman’s disease,” The Journal of Pathology, vol. 183, pp. 44–50, 1997. View at Publisher · View at Google Scholar
  140. F. Bertolini, M. Paolucci, F. Peccatori et al., “Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 106, no. 2, pp. 504–509, 1999. View at Publisher · View at Google Scholar · View at Scopus
  141. P. Salven, L. Teerenhovi, and H. Joensuu, “A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma,” Blood, vol. 90, no. 8, pp. 3167–3172, 1997. View at Google Scholar · View at Scopus
  142. I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis, “Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962,” Clinical Cancer Research, vol. 12, no. 23, pp. 6978–6984, 2006. View at Publisher · View at Google Scholar · View at Scopus
  143. K. Ganjoo, C. An, M. Robertson et al., “Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis,” Leukemia and Lymphoma, vol. 47, no. 6, pp. 998–1005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. A. T. Stopeck, J. M. Unger, L. M. Rimsza et al., “A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515,” Blood, vol. 120, no. 6, pp. 1210–1217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. http://clinicaltrials.gov/ct2/show/NCT00096148.
  146. L. Wang, W.-Y. Shi, F. Yang et al., “Bevacizumab potentiates chemotherapeutic effect on t-leukemia/lymphoma cells by direct action on tumor endothelial cells,” Haematologica, vol. 96, no. 6, pp. 927–931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. D. A. Bujanda, “Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab,” Annals of Oncology, vol. 19, no. 2, pp. 396–397, 2008. View at Publisher · View at Google Scholar · View at Scopus